Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Monopar Therapeutics Inc (MNPR)

Monopar Therapeutics Inc (MNPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 104,025
  • Shares Outstanding, K 5,278
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,400 K
  • EBIT $ -7 M
  • EBITDA $ -7 M
  • 60-Month Beta 1.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 15.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.31
  • Number of Estimates 2
  • High Estimate -0.29
  • Low Estimate -0.34
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +48.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.50 +340.78%
on 10/23/24
38.50 -48.48%
on 10/24/24
+14.58 (+277.81%)
since 10/22/24
3-Month
2.25 +781.56%
on 08/29/24
38.50 -48.48%
on 10/24/24
+17.07 (+618.66%)
since 08/22/24
52-Week
1.37 +1,348.34%
on 11/27/23
38.50 -48.48%
on 10/24/24
+18.29 (+1,183.82%)
since 11/22/23

Most Recent Stories

More News
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

MNPR : 19.66 (-0.25%)
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

MNPR : 19.66 (-0.25%)
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

MNPR : 19.66 (-0.25%)
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

MNPR : 19.66 (-0.25%)
MarketBeat Week in Review – 10/21- 10/25

Equities had a mixed week, but the tech-heavy NASDAQ powered to an all-time high; big tech earnings and key economic reports could bring more volatility

NVDA : 141.75 (-3.35%)
META : 559.23 (-0.69%)
GTLB : 66.35 (+2.39%)
MNPR : 19.66 (-0.25%)
RKLB : 23.34 (+4.15%)
GS : 602.98 (+1.15%)
SERV : 8.34 (-1.42%)
TSLA : 352.61 (+3.82%)
TLN : 213.22 (-3.03%)
AMD : 138.12 (+0.46%)
SOFI : 15.70 (+4.60%)
UBER : 71.12 (+2.13%)
Monopar Therapeutics Skyrockets 400% on Licensing Deal

Monopar Therapeutics (NASDAQ: MNPR) surged over 400% on Thursday after securing a licensing deal with AstraZeneca for a once-terminated Phase 3 drug.

MNPR : 19.66 (-0.25%)
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate

MNPR : 19.66 (-0.25%)
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024

MNPR : 19.66 (-0.25%)
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers

MNPR : 19.66 (-0.25%)
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers

MNPR : 19.66 (-0.25%)

Business Summary

Monopar Therapeutics Inc. is a biopharmaceutical company. It is focused on developing drugs for cancer patients. The company's intellectual property pipeline consists of Validive(R), Camsirubicin (MNPR-201) and MNPR-101 which are in clinical stage. Monopar Therapeutics Inc. is based in Wilmette, United...

See More

Key Turning Points

3rd Resistance Point 21.10
2nd Resistance Point 20.55
1st Resistance Point 20.13
Last Price 19.66
1st Support Level 19.16
2nd Support Level 18.61
3rd Support Level 18.19

See More

52-Week High 38.50
Fibonacci 61.8% 24.32
Fibonacci 50% 19.93
Last Price 19.66
Fibonacci 38.2% 15.55
52-Week Low 1.37

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar